BIOPOC Stock Overview
An in-vitro diagnostics company, provides biomarker tools and antibodies for clinical research in Europe, North America, Asia, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
BioPorto A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 2.35 |
| 52 Week High | DKK 2.86 |
| 52 Week Low | DKK 1.81 |
| Beta | 1.46 |
| 1 Month Change | 0% |
| 3 Month Change | -1.26% |
| 1 Year Change | n/a |
| 3 Year Change | -14.86% |
| 5 Year Change | -25.52% |
| Change since IPO | 8.29% |
Recent News & Updates
Recent updates
Shareholder Returns
| BIOPOC | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | -4.4% | -2.6% |
| 1Y | n/a | -22.3% | 2.7% |
Return vs Industry: Insufficient data to determine how BIOPOC performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how BIOPOC performed against the UK Market.
Price Volatility
| BIOPOC volatility | |
|---|---|
| BIOPOC Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.5% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: BIOPOC has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine BIOPOC's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1917 | 39 | Tony Pare | bioporto.com |
BioPorto A/S, an in-vitro diagnostics company, provides biomarker tests and tools, and antibodies for clinicians and researchers in Europe, North America, Asia, and internationally. It offers the neutrophil gelatinase-associated lipocalin test, a quantitative particle-enhanced turbidimetric immunoassay designed to run on automated chemistry analyzers; monoclonal antibodies for scientific, pharmaceutical, and clinical research; and enzyme-linked immunosorbent assay kits, as well as generic rapid assay device for custom lateral flow assays. The company was incorporated in 1917 and is based in Hellerup, Denmark.
BioPorto A/S Fundamentals Summary
| BIOPOC fundamental statistics | |
|---|---|
| Market cap | DKK 528.59m |
| Earnings (TTM) | -DKK 74.95m |
| Revenue (TTM) | DKK 30.51m |
17.3x
P/S Ratio-7.1x
P/E RatioIs BIOPOC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIOPOC income statement (TTM) | |
|---|---|
| Revenue | DKK 30.51m |
| Cost of Revenue | DKK 10.10m |
| Gross Profit | DKK 20.40m |
| Other Expenses | DKK 95.36m |
| Earnings | -DKK 74.95m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
Aug 01, 2023
| Earnings per share (EPS) | -0.22 |
| Gross Margin | 66.88% |
| Net Profit Margin | -245.68% |
| Debt/Equity Ratio | 0% |
How did BIOPOC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/05/28 05:18 |
| End of Day Share Price | 2023/02/28 00:00 |
| Earnings | 2023/03/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
BioPorto A/S is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Brookline Capital Markets |
| Jyoti Prakash | Edison Investment Research |
| Yi Chen | H.C. Wainwright & Co. |